Moreover, while BCL2 transgenic mice only develop tumors with a low frequency or after cooperation with other oncogenes (e.g., MYC), MCL1 transgenic mice were shown to develop lymphomas (predominantly FL and DLBCL) with high probability (>80%), although with a long latency (over 6 months) [22,137]. The gene discussed is MCL1; the disease is diffuse large B-cell lymphoma.